Updates

Announcements

Extension of Warrants in Incanthera plc

Aug 21, 2023

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that the Company has agreed with Incanthera plc (“Incanthera”) that Warrants issued to the Company on 26 February 2020, in conjunction with Incanthera’s IPO onto the Aquis Exchange, are extended by 12 months. Key highlights: The Company entered into a Warrant…
Board strengthened Ahead of next phase of company progression

Aug 11, 2023

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides notification of changes to its Board of Directors. It has been a pivotal 2023 for ImmuPharma, specifically within its P140 autoimmune platform. Most recently in June, the Company announced that, after receiving comprehensive guidance from the Food & Drug Administration (“FDA”) on the new…
2023 Result of Annual General Meeting – All Resolutions Passed

Jul 2, 2023

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed, details of which are contained in the table below. Resolution For % For Against % Against Withheld 1. To receive the accounts of the Company for the year…
Phase 2/3 adaptive clinical trial of P140 (Lupuzor™) in Lupus to commence following FDA meeting

Jun 19, 2023

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that the Phase 2/3 adaptive clinical trial of P140 (Lupuzor™) in patients with systemic lupus erythematosus (“SLE/Lupus”) is to commence in H2 2023. Key highlights: Following the receipt of comprehensive guidance from the Food and Drug Administration (“FDA”) in 3 separate…
Immupharma PLC Warrants Outstanding

Jun 16, 2023

To view warrants outstanding click here
Notice of AGM & Annual Report & Accounts

Jun 6, 2023

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting (“AGM”) has today been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2022 has also been posted to shareholders today. These documents will be available shortly, in electronic form,…
Positive guidance from the FDA Pre-IND meeting supports an IND application and a Phase 2/3 adaptive clinical trial of P140 in CIDP

May 18, 2023

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce further positive progress in its late-stage clinical program in patients with chronic idiopathic demyelinating polyneuropathy (“CIDP”), which is a further debilitating auto-immune condition within the Company’s P140 platform Key highlights: ImmuPharma has received positive support and guidance from the Food and…
TR1 Lanstead holding 10 May 2023

May 11, 2023

TR-1: Standard form for notification of major holdings To view click here
FINAL RESULTS ANNOUNCEMENT for the year ended 31 December 2022

May 11, 2023

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2022 (the “Period”). Key Highlights (including post Period review) Financial Loss for the Period of £3.8m (2021: £8.2m) Research and development expenses of £2.0m (2021: £3.7m) Administrative expenses of £0.8m…
FDA confirms Type-C meeting date of 7th June 2023 for Phase 2/3 adaptive study of Lupuzor™ in lupus

Apr 19, 2023

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that the Food and Drug Administration (“FDA”) has set a date of 7th June 2023 for a Type-C meeting to provide guidance on the Phase 2/3 adaptive study of Lupuzor™ (“P140”) in patients with systemic lupus erythematosus (“SLE/Lupus”). This follows on…
ImmuPharma receives confirmation of pre-IND meeting date with FDA for a Phase 2/3 adaptive study of P140 in CIDP

Apr 12, 2023

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce further positive progress in its late-stage P140 clinical program in patients with chronic idiopathic demyelinating polyneuropathy (“CIDP”). Key highlights: ImmuPharma has received confirmation from the Food and Drug Administration (“FDA”) for a pre- Investigational New Drug meeting date of 16 May…
Avion submits clinical protocol of Phase 2/3 adaptive study of Lupuzor™ in lupus to FDA

Mar 27, 2023

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to update the market on the next positive step in its Lupuzor™ (P140) program in patients with systemic lupus erythematosus (“SLE/Lupus”). This follows on from the recent announcement on 6 February 2023. Key highlights Avion Pharmaceuticals (“Avion”) and ImmuPharma agreed in February on…
Collaboration with Orano on ImmuPharma’s peptide technology as a vector for cancer radiotherapy

Mar 7, 2023

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce that it has signed an initial collaboration agreement on the Company’s peptide technology, with Orano SA (“Orano”), a leading international corporation and a key player in the nuclear energy sector. Key points: Orano has paid a small undisclosed amount to ImmuPharma…
Phase 2/3 adaptive study design for Lupus study agreed with Avion

Feb 6, 2023

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides an update to the market on its Lupuzor™ programme in patients with systemic lupus erythematosus (“SLE”) Key highlights: In conjunction with its partner Avion Pharmaceuticals (“Avion”), ImmuPharma confirms that a Phase 2/3 adaptive trial will be the best design for the next clinical study…
Major Interest | TR1 | Gary Smith

Jan 5, 2023

Notification of major holdings Click here
Major Interest | TR1 | Lanstead Capital – 3 January 2023

Jan 3, 2023

NOTIFICATION OF MAJOR HOLDINGS Click here
Grant of Share Options

Dec 22, 2022

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the grant of share options as follows. The Remuneration Committee (comprising the Non Executive Directors) has determined to award Share Options to the Executive Directors with exercise prices and conditions which reflect the underlying objective of restoring and enhancing shareholder value as follows: Tim…
End of Year Update

Dec 22, 2022

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides an update to the market. Review of 2022 and Outlook for 2023 As we approach the end of 2022 the Company can confirm that it continues to work proactively, together with our partner Avion Pharmaceuticals (“Avion) and external advisors, on the preparations around the…
Avion confirms its continued support to the Lupuzor™ clinical program in Lupus whilst exploring broader collaboration opportunities

Nov 18, 2022

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to update the market on a recent meeting in Atlanta, USA with our US partner, Avion Pharmaceuticals, LLC (“Avion”) for strategic discussions around ImmuPharma’s Lupuzor™ clinical program. This included Avion continuing its support to the clinical program of Lupuzor™ for Lupus, as well…
Lupuzor™ Update

Sep 30, 2022

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides an update on Lupuzor™, following the Company’s recent announcement on 14 September 2022, that its US partner for Lupuzor™ (P140), Avion Pharmaceuticals (“Avion”), had received a written response from the Food and Drug Administration (“FDA”) to the Type C meeting. In summary, the FDA…
INTERIM RESULTS for the six months ended 30 June 2022

Sep 30, 2022

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2022 (the “Period”). Key Highlights (including post Period review) Financials Financial performance in line with expectations over the Period Loss for the Period of £1.7m (30 June 2021: £3.7m)…

2026 (11)

2025 (24)

2024 (19)

2023 (25)

2022 (27)

2021 (21)

2020 (40)

2019 (19)

2018 (22)

2017 (17)

2016 (25)

2015 (17)

2014 (12)

A prodrug is a pharmacologically inactive or much less active compound that is converted inside the body (usually by metabolic enzymes) into the active drug that actually produces the therapeutic effect.

Lisa Baderoon

Non-Executive Director and Head of Investor Relations

Lisa has spent over 25 years working within the City of London being involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their financial and corporate strategies aligned to stakeholder and investor interests, as well as a strong acumen in media communication. During this time, she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPOs), secondary high profile capital raisings and mergers and acquisitions both in the UK and internationally.

Lisa had a successful career spanning 20 years as a Partner at Buchanan Communications, one of the leading City financial public relations agencies. As one of the youngest Board members, she was involved in the successful five-year earnout, as part of Buchanan being acquired by the FTSE 100 rated WPP Plc in 1997.

Lisa founded Just B Communications Ltd in 2012 with the key objective of working with a more select number of clients and providing a greater degree of bespoke advisory services thus becoming more integral to the day to day corporate and strategic development for these businesses. She has successfully advised a number of public and private companies, at Board level, on corporate strategy, stakeholder and investor communications, capital raisings, dual listings, licensing and M&A. Media profiling, where required, has also played an important role in advisory activities.

Lisa was appointed Head of Investor Relations at ImmuPharma in 2012 and most recently appointed as a Non-Executive Director in July 2021.

Ketan Patel

Independent Non-Executive Director

Ketan is an experienced investment professional who brings extensive expertise in financial markets, with a particular focus on the UK healthcare and life science sectors. He has been a long-term investor in UK markets, working as both an analyst and Fund Manager, managing institutional, retail, and charity mandates. Ketan began his career at JP Morgan before moving to Insight Investment, where he served as a global Pharmaceutical and Healthcare analyst. He then spent over 20 years at EdenTree Investment Management, where he was responsible for UK equity and global equity income strategies, consistently delivering upper-quartile performance.

Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes. Ketan is a CFA Charterholder and holds an MSc in Economic History from the London School of Economics, an MSc in Geography from King’s College London, and a BA (Hons) in History and Geography from Queen Mary University, London.

Dr Laurence Reilly MD, LLM

Senior Independent Non-Executive Director

Dr Laurence Reilly has been appointed as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.

He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.

Through his consulting practice (Acumen Life Science Investment Consulting) Dr Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr. Reilly previously served as a Clinician – Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor.

Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

Dr Tim Franklin PhD, MBA

Chief Operating Officer

Tim has 38 years’ experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Dr Laura Mauran-Ambrosino Ph.D.

Head of R&D

Born in Montpellier, France, Dr. Mauran-Ambrosino obtained her PhD in Chemistry from the Université de Bordeaux as a CIFRE fellow under the co-supervision of Dr. Goudreau. She then conducted postdoctoral research in cell biology at the Centre Hospitalier Universitaire (CHU) Pellegrin in Bordeaux.

In 2018, she joined Ureka, where she established both the Biology and Analytical Chemistry departments. In 2021, she became Chief Scientific Officer of Ureka Pharma. Since 2025, Dr. Mauran-Ambrosino has served as Head of R&D of the ImmuPharma Group.

Dr. Mauran-Ambrosino was a key contributor to the development of several programs, including BioAMB, BioCIN, the P140 companion diagnostic, and Kapiglucagon.

Ashley Clarke ACA

Chief Financial Officer & Company Secretary

Ashley brings over a decade of experience in the financial sector. She began her career at a Big Four accounting firm and later advanced her professional expertise by earning her ACA qualification with a respected local firm.

Her professional journey is rooted in auditing, where she developed expertise working with a diverse portfolio of audit and non-audit clients across various industries. Ashley’s experience spans from supporting SMEs to managing large international group consolidations, giving her a comprehensive understanding of financial management across different business scales.

Ashley has been closely involved with the company’s accounts for several years via outsourced accountants, providing her with deep familiarity with its operations. Now, as Group CFO and Company Secretary, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure robust fiscal management.

Dr Sébastien R. Goudreau Ph.D.

Chief Scientific Officer

Born in Sherbrooke, Québec, Canada, Dr. Sébastien Goudreau obtained his PhD in Chemistry from the Université de Montréal as an NSERC fellow before conducting postdoctoral research at ETH Zürich as an FRQNT fellow. He later returned to Canada, where he co-founded FindMolecule Inc. and worked in the pharmaceutical industry.

Dr. Goudreau joined ImmuPharma in 2014 as Research Director and established the Ureka research laboratories in Bordeaux. Following the merger of ELRO and Ureka in 2019, he became Chief Scientific Officer of Ureka Pharma. In 2021, he was appointed Chief Executive Officer of ImmuPharma Biotech, and since 2025 he has served as Chief Scientific Officer of the ImmuPharma Group.

Dr. Goudreau and his team are credited with the discovery and development of several innovative programs, including BioAMB, BioCIN, the P140 companion diagnostic, and Kapiglucagon.

Tim McCarthy FCCA, MBA

Chief Executive Officer

Tim has 40 years’ international senior level business experience in high growth biotech, healthcare and technology companies. He is also Chairman of Incanthera plc. Tim was formerly Chairman of 4basebio plc and CEO and CFO of a number of UK public listed and private companies including, Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, he has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.

Announcements

Extension of Warrants in Incanthera plc

Board strengthened Ahead of next phase of company progression

2023 Result of Annual General Meeting – All Resolutions Passed

Phase 2/3 adaptive clinical trial of P140 (Lupuzor™) in Lupus to commence following FDA meeting

Immupharma PLC Warrants Outstanding

Notice of AGM & Annual Report & Accounts

Positive guidance from the FDA Pre-IND meeting supports an IND application and a Phase 2/3 adaptive clinical trial of P140 in CIDP

TR1 Lanstead holding 10 May 2023

FINAL RESULTS ANNOUNCEMENT for the year ended 31 December 2022

FDA confirms Type-C meeting date of 7th June 2023 for Phase 2/3 adaptive study of Lupuzor™ in lupus

ImmuPharma receives confirmation of pre-IND meeting date with FDA for a Phase 2/3 adaptive study of P140 in CIDP

Avion submits clinical protocol of Phase 2/3 adaptive study of Lupuzor™ in lupus to FDA

Collaboration with Orano on ImmuPharma’s peptide technology as a vector for cancer radiotherapy

Phase 2/3 adaptive study design for Lupus study agreed with Avion

Major Interest | TR1 | Gary Smith

Major Interest | TR1 | Lanstead Capital – 3 January 2023

Grant of Share Options

End of Year Update

Avion confirms its continued support to the Lupuzor™ clinical program in Lupus whilst exploring broader collaboration opportunities

Lupuzor™ Update

INTERIM RESULTS for the six months ended 30 June 2022